Background: Two recent studies (ABC-02 [UK] and BT22 [Japan]) have demonstrated the superiority of cisplatin and gemcitabine (CisGem) chemotherapy over gemcitabine (Gem) alone for patients with pathologically proven advanced biliary tract cancer (BTC: cholangiocarcinoma, gallbladder and ampullary cancers). This pre-planned analysis evaluates the efficacy of CisGem with increased statistical power.
patients with good performance status (PS 0-1): HR for PFS is 0.61 (95% CI 0.51-0.74), P < 0.001 and OS HR = 0.64 (95% CI 0.53-0.77), P < 0.001. CisGem resulted in improved PFS and OS for intra-and extra-hepatic cholangiocarcinomas and gallbladder cancer. The treatment effect between UK and Japanese patients was consistent with respect to OS (HR = 0.65, 95% CI 0.53-0.79 and 0.65, 95% CI 0.42-1.03, respectively); with similar OS in the combination arms (median 11.7 and 11.1 months, respectively). Subgroups least likely to benefit included patients with ampullary tumours and poor performance status (PS2).
Conclusions:
CisGem is the standard of care for the first-line treatment of good-PS patients with advanced BTC regardless of ethnicity. Future studies should aim to enhance the effectiveness of this regimen in the first-line setting, establish the role of subsequent (second-line) therapy and assess the role of rationally developed molecular-targeted therapies. Key words: biliary tract cancer, cholangiocarcinoma, gallbladder cancer, cisplatin, gemcitabine introduction Biliary tract cancer (BTC) is a collective term to include cancers arising from the gallbladder, bile ducts (intra-hepatic, hilar or extra-hepatic cholangiocarcinoma, depending on their site of origin) and ampulla of Vater adenocarcinomas. Although considered relatively rare in the US (with 5000 new cases diagnosed annually [1] ) and European countries (e.g. UK incidence: 1200 cases per annum [UK National Statistics homepage at http ://www.statistics.gov.uk]), it has a much higher prevalence in Latin America [2] and East Asia. In Japan, the incidence is 10-fold that seen in the West with 17 311 deaths from BTC in 2007 making it the sixth leading cause of cancer death [3] . Moreover, the incidence, particularly of intra-hepatic cholangiocarcinoma, has been increasing in the US, Japan, UK and Australia since the 1970s, [4] [5] [6] increasing the need for effective cancer services.
Surgery remains the optimal modality of therapy leading to long-term survival for patients diagnosed with resectable disease. However, most patients have advanced (inoperable or metastatic) disease at presentation, often in the context of biliary obstruction and sepsis and age-related co-morbidities resulting in a 5-year survival of 5%-15% [7, 8] .
Two phase III studies have demonstrated improved survival of chemotherapy over best supportive care (BSC) for patients with advanced (inoperable) disease. A Swedish study reported a median survival of 6 months in patients with mixed biliary and pancreatic cancers treated with 5-fluorouracil (5-FU), etoposide and leucovorin chemotherapy compared with 2.5 months with BSC [9] . A study from India in patients with gallbladder cancer demonstrated an improvement in median survival from 4.5 to 9.5 months using a gemcitabine and oxaliplatin regimen [10] . It can be concluded that the median survival in patients treated with , each on days 1 and 8 of a 21-day regimen) versus gemcitabine monotherapy (Gem, gemcitabine 1000 mg/m 2 on days 1, 8 and 15 of a 28-day regimen). It built on a randomised phase II study (ABC-01, at the time the largest global study with 86 patients) [12] , which had demonstrated an improvement in 6-month progression-free survival from 47.7% to 57.1%. ABC-01 was then extended to the phase III ABC-02 study using an identical protocol but recruiting an additional 324 patients for a total of 410 patients. This extension would provide statistical power for an overall survival (OS) analysis. This study demonstrated a statistically improved OS in favour of the combination arm [median OS 11.7 versus 8.1 months, hazard ratio (HR) 0.64; 95% confidence interval (CI) 0.52-0.80, P < 0.001] with an improved progression-free survival [PFS, median 8.0 versus 5.0 months, HR = 0.63, 95% CI 0.51-0.77, P < 0.001) and an acceptable toxicity profile, [13] thus setting a reference regimen for patients with advanced BTC.
In parallel, the biliary tract (BT) 22 study (ClinicalTrials.gov number NCT00380588) was developed in Japan in order to replicate the ABC-01 data using an identical regimen to the ABC studies. Compared with Gem, patients who received CisGem had a better 1-year survival (the primary end point, 39.0% versus 31.0%); median OS (11.2 versus 7.7 months); median PFS (5.8 versus 3.7 months) and radiological response rate (19.5% versus 11.9%). The hazard ratio between the treatment arms was 0.69 (95% CI 0.42-1.13) for OS and 0.66 (95% CI 0.41-1.05) for PFS in favour of CisGem [14] .
The meta-analysis reported here represents a pre-planned international collaboration between UK and Japanese investigators in order to achieve greater statistical power in the evaluation of the treatment effect.
patients and methods
The primary objective of this meta-analysis is to evaluate the effect of cisplatin and gemcitabine (CisGem) versus gemcitabine alone (Gem), with enhanced patient numbers by combining patient-level data from the ABC-01/ABC-02 and BT22 studies (Table 1 ). In addition, we sought to explore the relative treatment effect across both studies given the inherent differences between the study populations.
Each of the studies was carried out with Ethics Committee and other requisite approvals/notifications (governed by the country of each study sponsor); all patients were enrolled after giving informed consent to participate and the studies were conducted in accordance with the Declaration of Helsinki.
Gemcitabine was provided for the investigators in both studies by Lilly Oncology or Eli Lilly Japan, as appropriate. ABC-02 was carried out as an investigator-initiated academic study; Lilly Oncology was not involved in the accrual or analysis of the data, or the preparation of the manuscript. Data from ABC-02 were held by the study sponsor, University College London Clinical Trials Unit (UCL CTU). BT22 was originally a Lilly-sponsored trial although additional data collection for OS and PFS was made as an investigator-initiated study and supported by the Ministry of Health, Labour and Welfare (MHLW), Health Labour Sciences Research Grant; data were collected by the investigators and released following publication of BT22 to UCL CTU under a study-specific agreement for the sole purposes of this meta-analysis.
Cox proportional hazards model was used to estimate the effect of treatment on OS and PFS, providing a HR for CisGem versus Gem. The treatment effect was examined for each of the subgroups for pre-specified baseline factors, as well as age, sex and trial. A test for interaction with treatment was assessed for each set of subgroups.
OS was estimated from date of entry to the trial to date of death, or date last seen alive; PFS was estimated from date of entry to the trial until date of Table 2) . Threequarters of the patients had metastatic disease; 89% of patients had a good performance status (PS, 0-1) ( patients with PS of 2 were eligible for ABC-02, but not BT22); and the histology was of adenocarcinoma type in 93% with a small number of patients with alternative histologies (Table 2) . Sixty-eight percent of patients had prior therapy, primarily in the form of biliary stenting; a total of 109 patients (22%) had undergone prior surgery with curative intent and subsequently relapsed; prior systemic chemotherapy for advanced disease was not allowed. These data had slightly longer follow-up in both trials (median follow-up in ABC-02: 9.2 months; BT22: 9.0 months), compared with the published papers [13, 14] . When compared with gemcitabine monotherapy, the combination of cisplatin and gemcitabine was associated with an improved PFS (median 8.8 versus 6.7 months; HR = 0.64 (95% CI 0.53-0.76), P < 0.001) and OS (median 11.6 versus 8.0 months; HR = 0.65 (95% CI 0.54-0.78), P < 0.001), Figure 1a and b, respectively. Thus, the use of combination chemotherapy reduces the risk of progression or death (defined by PFS event) by 36%; and risk of death by 35%, compared with gemcitabine monotherapy. Exploratory subgroup analysis suggests that all patients benefit from CisGem versus Gem with respect to sex; age (<65 and ≥65 years), stage of disease (locally advanced and metastatic); site of primary tumour (intra-hepatic, extra-hepatic cholangiocarcinoma and gallbladder cancer); performance score (PS 0 and 1) and use of prior therapy (Figures 2 and 3) . The widest confidence intervals are seen in patients with ampullary tumours and those with PS 2 due to the small size of each cohort (n = 24 and n = 52, respectively). When limited to patients with PS 0-1 only (n = 441), the HR for PFS is 0.61 (95% CI 0.51-0.74), P < 0.001 and for OS HR = 0.64 (95% CI 0.53-0.77), P < 0.001.
There is no evidence for a difference in treatment effects between any of the subgroups for PFS or OS (Figures 2 and 3) . The treatment effect is remarkably similar between the two studies (BT22 versus ABC-02) with respect to OS (Figure 3 ; HR = 0.65 for both trials) and PFS ( Figure 2) [test for heterogeneity for OS: P = 0.90; PFS: P = 0.14].
A total of 109 patients had surgery before trial entry; there is no evidence of an interaction between prior surgery status and treatment effect for OS and PFS (P = 0.52 and P = 0.26, respectively).
discussion
It was previously believed that the incidence of BTC was too low for prospective, adequately powered clinical studies to be carried out. This meta-analysis, achieved by international collaboration, combines individual patient-level data from two prospective randomized, controlled trials in pathologically proven, advanced BTC using the same treatment comparisons [the UK ABC-02 phase III study (n = 410) and Japanese BT22 randomised phase II study (n = 84)] and thus represents the largest prospectively evaluated patient pool with close to 500 patients in total. This meta-analysis demonstrates a significant improvement in PFS and OS in favour of cisplatin and gemcitabine doublet chemotherapy over gemcitabine monotherapy, of the order of a 35% reduction in the risk of outcome.
There is a striking consistency between the treatment effect observed between the ABC-02 and BT22 studies (both HRs = 0.65) with respect to OS (Figure 3 ) with near-reproducible median survival in the combination arms (11.7 and 11.1 months, respectively). The similarity is less marked for PFS (HR 0.65 and 0.55), with median PFS of 9.7 and 6.5 months in each of the combination arms of ABC-02 and BT22, respectively. This is likely to be due to differences in protocol-driven assessments; specifically frequency of radiological tumour reassessment (6-weekly in BT22 and 12-weekly in ABC-02) [15] .
This meta-analysis did not include an assessment of toxicity due to the different schedules for safety assessment between the protocols (specifically, BT22 included assessment of complete blood count and biochemistry on the rest week of treatment (not required for ABC-02) which may explain the increased haematological toxicity reported in this study; [15] however, these regimens are well established and toxicities are detailed in the individual study publications [13, 14] . Patients with a good PS (0-1) appear to derive greater benefit from combination chemotherapy (HR for PFS and OS are 0.61 and 0.64, respectively). It is therefore appropriate for future studies using this combination chemotherapy to limit inclusion to PS 0-1 patients. PS2 patients were only included in the ABC-02 study and the HR for OS for this group was 0.88, 95% CI 0.50-1.56; thus, in the absence of studies specifically addressing therapy for PS2 patients, it may be preferable to consider gemcitabine monotherapy for this group given the very poor survival with BSC alone [9, 10] .
With the exception of ampullary tumours combination chemotherapy resulted in statistically significantly favourable PFS and OS for all other tumour-location subgroups (intrahepatic cholangiocarcinoma, extra-hepatic cholangiocarcinoma and gallbladder cancer). Although a reduced risk of 25%-30% was seen in the ampullary group, the small numbers did not permit a statistically meaningful result. As these cancers are uncommon, it may be necessary for another meta-analysis to provide the statistical power required for a robust assessment of this tumour subtype in future studies.
The remit of this meta-analysis is limited to the effect of firstline chemotherapy for patients with advanced BTC. The use of subsequent chemotherapy can confound the survival analysis. Only 18% of patients in the ABC-02 study went on to receive second-line chemotherapy, primarily due to there being no UKrecognised regimen in this setting. In contrast, 76% of patients in BT22 went on to receive second-line chemotherapy on disease progression in Japan where the oral fluoropyrimidine, S1, is a licensed treatment option for these patients. Despite this disparity, the survival in the combined arms was very similar as already discussed, accepting the inherent limitations of crossstudy comparisons. There are no randomised phase III data that second-line chemotherapy improves survival for patients who have previously been treated with cisplatin and gemcitabine; specifically, no phase III studies have ever been carried out. A recent large retrospective single-centre series suggests that second-line chemotherapy (after a heterogeneous group of firstline regimens) is feasible in ∼25% of patients; [16] moreover, after cisplatin and gemcitabine first-line chemotherapy, we have shown that patients who do go on to receive chemotherapy may derive additional benefit (median survival from start of secondline treatment: 8.1 months, median survival from start of firstline chemotherapy: 19.5 months) [17] . However, such analysis is highly subject to selection bias and prospective studies are This meta-analysis for efficacy, together with a recently published cost-effectiveness analysis [18] has strengthened the rationale for recommending cisplatin and gemcitabine as a reference regimen for development of further therapies across international patient populations with advanced BTC.
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